Howard Hauptman, MD
Rheumatology · Baltimore, MDNPI 1861461220
Payments from drug & device makers
Across 282 payments — averaging $162.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$22K
- Boehringer Ingelheim$6K
- UCB, Inc.$5K
- Janssen Research & Development, LLC$5K
- Johnson & Johnson$2K
- Sanofi US Services Inc.$2K
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $22,242 |
| Boehringer Ingelheim | 11 | $6,406 |
| UCB, Inc. | 22 | $5,102 |
| Janssen Research & Development, LLC | 7 | $5,094 |
| Johnson & Johnson(2 entities) | 15 | $1,755 |
| Sanofi US Services Inc. | 5 | $1,680 |
| Amgen(2 entities) | 36 | $813 |
| AbbVie | 26 | $455 |
| Pfizer | 22 | $294 |
| Novartis | 12 | $266 |
| E.r. Squibb & Sons, L.L.C. | 16 | $221 |
| Lilly USA, LLC | 14 | $191 |
| Bristol Myers Squibb | 10 | $183 |
| Radius Health, Inc. | 6 | $155 |
| Regeneron Healthcare Solutions, Inc. | 7 | $145 |
| Genentech USA, Inc. | 10 | $121 |
| AstraZeneca(2 entities) | 5 | $111 |
| Sanofi | 5 | $98 |
| Aurinia Pharma U.S., Inc. | 3 | $72 |
| Invivyd Inc | 2 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Hikma Pharmaceuticals USA | 3 | $39 |
| Merck | 3 | $38 |
| Pacira Therapeutics, Inc. | 2 | $33 |
| Fresenius Kabi USA, LLC | 1 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Fidia Pharma USA Inc. | 3 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Qiagen, LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Medexus Pharma, Inc. | 1 | $12 |
How this compares
$45,827 in reported general payments places this provider in the 80th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Baltimore
- Thomas Grader BeckBaltimore$1.2M
- Michelle PetriBaltimore$1.1M
- Laura HummersBaltimore$1M
- Lisa ChristopherBaltimore$370K
- Violeta RusBaltimore$358K
- Ami ShahBaltimore$347K
- Alan BaerBaltimore$277K
- Clifton BinghamBaltimore$210K
- Homa TimlinBaltimore$152K
- Marc HochbergBaltimore$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.